Lung Cancer Fact Sheet. 2022 [cited 2022 May 12]. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/resource-library/lung-cancer-fact-sheet. p.MsoNormal, li.MsoNormal, div.MsoNormalAvailable from: font-size:11.0ptAvailable from: }a:link, span.MsoHyperlinkAvailable from: }a:visited, span.MsoHyperlinkFollowedAvailable from: font-size:11.0ptAvailable from: mso-ansi-font-size:11.0ptAvailable from: mso-bidi-font-size:11.0ptAvailable from: }div.WordSection1.
Cancer facts and figures. 2022 [cited 2022 May 12]. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html. Accessed 10 May 2022.
Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10(11):760–74.
CAS PubMed PubMed Central Article Google Scholar
Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179–84.
CAS PubMed PubMed Central Article Google Scholar
Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–61.
CAS PubMed PubMed Central Article Google Scholar
Ramalingam SS, Vansteenkiste J, Planchard D, Chul Cho B, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50.
CAS PubMed Article Google Scholar
Herbst RS, Tsuboi M, John T, Grohe C, Majem M, Goldman JW, et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. J Clin Oncol. 2020;38(18_suppl):LBA5.
Smeltzer MP, Wynes MW, Lantuejoul S, Soo R, Ramalingam SS, Varella-Garcia M, et al. The International Association for the study of lung cancer global survey on molecular testing in lung cancer. J Thorac Oncol. 2020;15(9):1434–48.
Ren S, Wang J, Ying J, Mitsudomi T, Lee DH, Wang Z, et al. Consensus for HER2 alterations testing in non-small-cell lung cancer. ESMO Open. 2022;7(1): 100395.
CAS PubMed PubMed Central Article Google Scholar
Sheikine Y, Rangachari D, McDonald DC, Huberman MS, Folch ES, VanderLaan PA, et al. EGFR testing in advanced non-small-cell lung cancer, a mini-review. Clin Lung Cancer. 2016;17(6):483–92.
CAS PubMed Article Google Scholar
Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS ONE. 2015;10(10): e0140712.
PubMed PubMed Central Article Google Scholar
Non-Small Cell Lung Cancer. [cited 2022 May 12]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450. Accessed 10 May 2022.
Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, et al. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Lung Cancer. 2014;85(2):161–7.
Lin HM, Yin Y, Crossland V, Wu Y, Ou SHI. EGFR testing patterns and detection of EGFR Exon 20 insertions in the United States. JTO Clin Res Rep. 2022;3(3): 100285.
PubMed PubMed Central Google Scholar
Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Rev BA, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12(2):220–9.
CAS PubMed PubMed Central Article Google Scholar
Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 2011;1(4):352–65.
CAS PubMed PubMed Central Article Google Scholar
Yang M, Xu X, Cai J, Ning J, Wery JP, Li QX. NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors. Int J Cancer. 2016;139(1):171–6.
CAS PubMed Article Google Scholar
Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, et al. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget. 2015;6(36):38789–803.
PubMed PubMed Central Article Google Scholar
Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013;5(216):216ra177.
PubMed PubMed Central Article Google Scholar
Hasako S, Terasaka M, Abe N, Uno T, Ohsawa H, Hashimoto A, et al. TAS6417, A novel EGFR inhibitor targeting exon 20 insertion mutations. Mol Cancer Ther. 2018;17(8):1648–58.
CAS PubMed Article Google Scholar
Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18(18):4910–8.
CAS PubMed Article Google Scholar
Tomizawa K, Suda K, Onozato R, Kosaka T, Endoh H, Sekido Y, et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer. 2011;74(1):139–44.
Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997–2003.
Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate J, Witsuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006.
PubMed PubMed Central Article Google Scholar
Li BT, Ross DS, Aisner DL, Chaft JE, Hsu M, Kako SL, et al. HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J Thorac Oncol. 2016;11(3):414–9.
Network CGAR. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–50.
Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci USA. 2009;106(2):474–9.
CAS PubMed PubMed Central Article Google Scholar
Zhao S, Fang W, Pan H, Yang Y, Liang Y, Yang L, et al. Conformational landscapes of HER2 exon 20 insertions explain their sensitivity to kinase inhibitors in lung adenocarcinoma. J Thorac Oncol. 2020;15(6):962–72.
CAS PubMed Article Google Scholar
Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol. 2016;27(2):281–6.
Shah MP, Aredo JV, Padda K, Ramchandran KJ, Wakelee HA, Das MS, et al. EGFR exon 20 insertion NSCLC and response to platinum-based chemotherapy. Clin Lung Cancer. 2022;23(2):e148–53.
CAS PubMed Article Google Scholar
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.
CAS PubMed Article Google Scholar
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.
CAS PubMed Article Google Scholar
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.
CAS PubMed Article Google Scholar
Yang G, Li J, Xu H, Yang Y, Yang L, Xu F, et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020;145:186–94.
Xu CW, Wang WX, Wang D, Wang QM, Pu XX, Zhu YC, et al. Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. Transl Lung Cancer Res. 2020;9(5):1853–61.
CAS PubMed PubMed Central Article Google Scholar
Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. Cancer. 2015;121(18):3212–20.
CAS PubMed Article Google Scholar
Addeo A, Passaro A, Malapelle U, Banna GL, Subbiah V, Friedlaender A. Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treat Rev. 2021;96: 102179.
CAS PubMed Article Google Scholar
Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol. 2017;12(2):403–7.
留言 (0)